H-Index
75
Scimago Lab
powered by Scopus
JCR
Clarivate
Analytics
16%
Acceptance
Rate
call: +1.631.470.9640
Mon-Fri 10 am - 2 pm EST

Logo



eISSN: 1643-3750

Nano-Hydroxyapatite-Derived Drug and Gene Co-Delivery System for Anti-Angiogenesis Therapy of Breast Cancer

Lina Zhao, Wenhui Zhao, Ye Liu, Xue Chen, Yan Wang

Department of Hematology, Tumor Hospital Affiliated to Harbin Medical University, Harbin, Heilongjiang, China (mainland)

Med Sci Monit 2017; 23:4723-4732

DOI: 10.12659/MSM.902538

Available online:

Published: 2017-10-02


BACKGROUND: Breast cancer is among the deadliest cancers across the world and is responsible for countless deaths. There is an urgent need for co-delivery systems which can simultaneously transport both drug and gene into a single cancer cell with low toxicity and high anti-angiogenesis efficiency.
MATERIAL AND METHODS: In the present study, well-formed amine-functionalized hydroxyapatite nanoparticles based on combined angiogenesis therapy for breast cancer were successfully constructed for the simultaneous delivery of p53 and candesartan (CD) (p53/CD/NHAP).
RESULTS: In vitro and in vivo experiments revealed that p53/CD/NHAP can effectively transfer the p53 gene and deliver the loaded CD to achieve preferable anti-breast cancer effect both at the cellular level and in tumor-bearing mice. This may possibly be due to the combined anti-angiogenic mechanisms of p53 and CD via different pathways.
CONCLUSIONS: p53/CD/NHAP might be a candidate carrier for efficient anti-angiogenesis therapy of breast cancer.

Keywords: Angiogenesis Inhibitors, Angiotensin II Type 1 Receptor Blockers, Genes, p53, Hydroxyapatites, Inflammatory Breast Neoplasms



Back